Wealth Enhancement Trust Services
VRDN icon

Wealth Enhancement Trust Services’s Viridian Therapeutics VRDN Stock Holding History

Wealth Enhancement Trust Services’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-20
Closed -$367 – 1495
2026
Q2 		$367 Buy
+20
New +$322 ﹤0.01% 1288

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Wealth Enhancement Trust Services's VRDN Position: Q3 2026 in Review

Wealth Enhancement Trust Services sold out of Viridian Therapeutics (VRDN) in Q3 2026, closing a stake of 20 shares — an estimated $367 sold.

Wealth Enhancement Trust Services first reported a position in VRDN in Q2 2026 and held it in 1 quarter. The position peaked at $367 in Q2 2026. 154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Wealth Enhancement Trust Services reported no remaining Viridian Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Trust Services sold 20 Viridian Therapeutics shares in Q3 2026, an estimated $367.
  • Wealth Enhancement Trust Services first reported a position in Viridian Therapeutics in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Trust Services's Viridian Therapeutics position peaked at $367 in Q2 2026.
  • 154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q3 2026, filed 7 Oct 2026.